Aligos Therapeutics
South San Francisco, US · Founded 2018 · 3 known investors
Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.
Founders & leadership
Aligos Therapeutics was founded in 2018 by Leonid Beigelman and Lawrence M. Blatt.
LB
Leonid BeigelmanPresident
LM
Lawrence M. BlattChairman, President & CEO (Co-founder)
HA
Hardean AchneckExecutive
SC
Sushmita ChandaExecutive Vice President - Preclinical Development
BD
Brian DowdExecutive Vice President - Controller
LQ
Lucinda QuanExecutive Vice President - General Counsel
JS
Julian SymonsExecutive Vice President, Chief Scientific Officer
LA
Lesley Ann CalhounExecutive Vice President, Chief Operating Officer & Chief Financial Officer
SM
Sushmita M. ChandaExecutive Vice President, Chief Development Officer
JH
Jim HassardEVP, Chief Commercial Officer
DB
David B. SmithExecutive Vice President, Head of Chemical Operations
PM
Peter MoldtNamed on SEC filing
Investors · 3
Reported raises · per SEC filings
Form D private placements$282.2M disclosed across 3 rounds · 2019–2025
▶$105MraisedFeb 2025 · 12 investors · BiotechnologyRule 506(b)
▶$105MraisedFeb 2025 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Bridget MartellDirector
- Julian SymonsExecutive Officer
- Margarita ChavezDirector
- K. Peter HirthDirector
- Heather PrestonDirector
- Lesley Ann CalhounExecutive Officer
- Lawrence M. BlattExecutive Officer, Director
- James ScopaDirector
- Hardean AchneckExecutive Officer
- Carole NuechterleinDirector
- Offering amount
- $105M
- Amount sold
- $105M
- Sales commissions
- $2.7M
- Placement agents
- Piper Sandler & Co., Jefferies LLC
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$92.2MraisedNov 2023 · 11 investors · BiotechnologyRule 506(b)
▶$92.2MraisedNov 2023 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lesley Ann CalhounExecutive Officer
- Bridget MartellDirector
- Jack NielsenDirector
- Leonid BeigelmanExecutive Officer, Director
- Lucinda QuanExecutive Officer
- Carole NuechterleinDirector
- Julian SymonsExecutive Officer
- Lawrence BlattExecutive Officer, Director
- Matthew McClureExecutive Officer
- James ScopaDirector
- Peter HirthDirector
- Offering amount
- $92.2M
- Amount sold
- $92.2M
- Sales commissions
- $5.5M
- Placement agents
- PIPER SANDLER & CO.
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$85MraisedJan 2020 · 38 investors · BiotechnologyRule 506(b)
▶$85MraisedJan 2020 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter HirthDirector
- Carole NeuchterleinDirector
- Jack NielsenDirector
- Peter MoldtDirector
- Sushmita ChandaExecutive Officer
- Julian SymonsExecutive Officer
- Kathleen GlaubDirector
- Brian DowdExecutive Officer
- Lucinda QuanExecutive Officer
- Leonid BeigelmanExecutive Officer, Director
- Lawrence BlattExecutive Officer, Director
- Michael YiDirector
- Tom WoiwodeDirector
- John FryExecutive Officer
- Offering amount
- $125M
- Amount sold
- $85M
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Apogee Therapeutics20 shared keywordsApogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care. Its pipeline addresses dermatological, respiratory, and gastroenterological conditions.
Robinhood19 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Companies competing with Aligos Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Aligos Therapeutics do?
- Aligos is a clinical-stage biotechnology company developing therapeutics for liver and viral diseases, including chronic hepatitis B virus (HBV) infection and MASLD/MASH. Its pipeline targets conditions that are major causes of liver cancer and liver-related illness worldwide.
- Who founded Aligos Therapeutics?
- Aligos Therapeutics was founded by Leonid Beigelman, Lawrence M. Blatt in 2018.
- Who are Aligos Therapeutics's investors?
- Aligos Therapeutics's investors include Roche Venture Fund, MPM BioVentures 2014, Vivo Capital.
- How much funding has Aligos Therapeutics raised?
- Aligos Therapeutics has disclosed $282.2M raised across 3 rounds.
- Where is Aligos Therapeutics headquartered?
- Aligos Therapeutics is headquartered in South San Francisco, US.